REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.

Bayer stock has delivered a strong 75.8% return over the past year, and the current valuation checks suggest the shares may still be pricing in a discount rather than a premium. The 75.8% one year gain puts recent momentum front and centre and raises the question of how much value is already reflected in the share price. Expanded authorization in Canada for LYNKUET for vasomotor symptoms linked to breast cancer treatment can support expectations for Bayer's future revenue, while the ongoing...

Myqorzo's early launch momentum and global expansion could boost Cytokinetics, while pipeline progress may widen its growth opportunity.

Bayer (XTRA:BAYN) is drawing fresh attention after Health Canada expanded the indication for LYNKUET (elinzanetant) to treat moderate to severe vasomotor symptoms linked to adjuvant endocrine breast cancer therapy. See our latest analysis for Bayer. The Health Canada decision lands at a time when Bayer’s share price has climbed to €48.74, supported by a 24.24% 90 day share price return and a 74.01% 1 year total shareholder return. However, the 3 year total shareholder return is slightly...

GlobalData highlighted EyePoint’s Duravyu as a notable drug set to enter the wet AMD market by 2034.

EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.

Pharma's 2026 recovery puts Bayer, Eli Lilly and Johnson & Johnson in focus as innovation and M&A offset pricing and patent headwinds.

In the Large-Cap Pharmaceuticals industry, LLY, J&J and BAYRY are worth watching as the industry shows a strong recovery.

Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.

Europe’s adaptation to new temperatures could spell profit for other enterprises, such as electricity grids and water systems.

CYTK tops Q2 revenue estimates as Myqorzo gains traction, but higher launch costs and the absence of milestone payments weigh on results.

A hearing to consider the final approval of Bayer’s proposed $7.25 billion class settlement over its Roundup weedkiller has been postponed to Sept. 14.

Unexpectedly strong crop-science earnings and a lower debt forecast strengthened Bayer's quarterly financial picture.

Aug 5 (Reuters) - Bayer CropScience posted a 15.4% rise in first-quarter profit on Wednesday on lower expenses, even as a weak start to the monsoon weighed on demand.

Bayer (XTRA:BAYN) drew fresh attention after reporting Q2 2026 results and scheduling its earnings call for 4 August. The stock moved higher as investors reacted to the latest profit and revenue figures. See our latest analysis for Bayer. At a share price of €48.25, Bayer’s recent 1 day share price return of 2.40% and 7 day share price return of 2.59% follow Q2 earnings and product updates. The 30 day share price return is down 9.58% and the 90 day share price return of 25.29% alongside a 1...

Bayer’s recently reported Q2 2026 results showed sales of €10,872 million and a swing to net income of €219 million, with earnings per share returning to profit from a loss a year earlier. Over the first half of 2026, Bayer generated €24.28 billion in sales and €2.98 billion in net income while also advancing its pipeline and managing heavy litigation-related cash outflows that pushed free cash flow to €2.70 billion and net financial debt to €33.60 billion. With Bayer maintaining its 2026...